Paper: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

A phase 1b/2 study evaluating FLAG-IDA+VEN in 41 newly diagnosed AML patients had a 98% ORR (73% CR) and 66% went on to Allo. 39% had febrile neutropenia, 24% w/pneumonia and 19% bacteremia. There were 4 deaths all in the setting of relapsed disease.

Read the full article here

Related Articles